Here in the US, according to news reports issued late on Friday, a federal court in New Jersey invalidated the last remaining patent held by Johnson & Johnson on their formulation of abiraterone acetate, known as Zytiga, and used in the treatment of castration-resistant forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, acatate, access, patent, Zytiga | 6 Comments »
On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, cost, generic, patent, Zytiga | Leave a comment »
According to a story on the FiercePharma web site, the patent for sildenafil (Viagra) will expire today in Europe. This ought to lead to a significant drop in the price for a very popular drug as generic equivalents rapidly come available. Here in the USA, however, Pfizer has managed to extend the patent for Viagra to 2020 (through litigation).
Filed under: Living with Prostate Cancer | Tagged: generic, patent, sildenafil, Viagra | 2 Comments »
Earlier today, the Supreme Court of the United States (SCOTUS) ruled against Myriad Genetics in an important gene patenting case that we have discussed frequently on this site in the past couple of years. … READ MORE …
Filed under: Uncategorized | Tagged: gene, Myriad, patent, SCOTUS | Leave a comment »
Next Monday, after conflicting rulings in other courts over the past 4 years, the case of Association for Molecular Pathology v. Myriad Genetics will be fought out before the Supreme Court of the United States (SCOTUS). At stake is the complex issue of exactly what is patentable related to the isolation and use of portions of the human genome (and other, related issues). … READ MORE …
Filed under: Uncategorized | Tagged: gene, Myriad Genetics, patent, SCOTUS, Supreme Court | 2 Comments »
As regular readers may remember, The “New” Prostate Cancer InfoLink has been keeping an eye on the court case known as the Association for Molecular Pathology v. Myriad Genetics, Inc. The case relates to the rights of the biotechnology industry (or indeed any other organization or individual) to hold patents on human genes and/or their scientific uses. … READ MORE …
Filed under: Uncategorized | Tagged: gene, law, Myriad Genetics, patent | 2 Comments »
There are two ways to look at a ruling issued yesterday by the Indian controller general of patents, designs and trademarks: it can either be seen as a major victory for patients who had no prior hope of treatment with a highly effective anticancer agent because of its cost … or it can be seen as an international setback to the entire concept of patent and intellectual property law. … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, innovation, law, patent | 7 Comments »
As we have previously discussed, the question posed above is a highly controversial one, and there is a legal case in the U.S. — the case challenging Myriad Genetics ownership of patents on the BRCA1 and BRCA2 genes for specific types of breast cancer — which has now reached the Supreme Court (sometimes called SCOTUS by Washington insiders). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: gene, Myriad Genetics, patent, Supreme Court | 4 Comments »
In March 2010, as previously reported on this web site, a federal court judge initially ruled that the patents on the BRCA1 and BRCA2 genes held by Myriad Genetics and the University of Utah “are directed to a law of nature and were therefore improperly granted.” … READ MORE …
Filed under: Diagnosis, Management | Tagged: BRCA, gene, Myriad Genetics, patent | 1 Comment »
In a case that has major ramifications for the health care industry and for personalized medicine, a federal judge in New York yesterday invalidated the patents on BRAC1 and BRAC2 genes held by Myriad Genetics and the University of Utah. … READ MORE …
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: gene, patent, test | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 